# Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct07370688` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07370688](<https://clinicaltrials.gov/study/NCT07370688>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07370688

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 402 participants.

## Technical summary

Registry record NCT07370688. Randomized; no masking; primary purpose treatment. Start 2024-08-12 (actual); primary completion 2028-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 402 participants (planned count; ClinicalTrials.gov record NCT07370688, source copy `cardio:ctgov-nct07370688-2026-01-27`, retrieved 2026-10-26)
- Started: 2024-08-12 (actual) (ClinicalTrials.gov record NCT07370688, source copy `cardio:ctgov-nct07370688-2026-01-27`, retrieved 2026-10-26)
- Primary completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT07370688, source copy `cardio:ctgov-nct07370688-2026-01-27`, retrieved 2026-10-26)
- Completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT07370688, source copy `cardio:ctgov-nct07370688-2026-01-27`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT07370688, source copy `cardio:ctgov-nct07370688-2026-01-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07370688-2026-01-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation
- Acronym: IRON TAVI
- Condition: Aortic Valve Stenosis
- Condition: Iron Deficiency
- Condition: TAVI(Transcatheter Aortic Valve Implantation)
- Condition: Cardiovascular Diseases
- Intervention (Drug): Intravenous ferric carboxymaltose
- Lead sponsor: Erasmus Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Ferric carboxymaltose (`core:ferric-carboxymaltose`)
- Registry lists this organization as the lead sponsor: Erasmus Medical Center (`cardio:org-erasmus-medical-center`)

## Provenance

Content hash: f284f669cd275c77e4af3d3d5585a8b4dc73692cb7c4133a34373f9d354a58e3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
